Details for New Drug Application (NDA): 208223
✉ Email this page to a colleague
The generic ingredient in ZEMBRACE SYMTOUCH is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-seven suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for 208223
| Tradename: | ZEMBRACE SYMTOUCH |
| Applicant: | Tonix Meds |
| Ingredient: | sumatriptan succinate |
| Patents: | 3 |
Pharmacology for NDA: 208223
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
Suppliers and Packaging for NDA: 208223
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ZEMBRACE SYMTOUCH | sumatriptan succinate | SOLUTION;SUBCUTANEOUS | 208223 | NDA | Upsher-Smith laboratories, LLC | 0245-0809 | 0245-0809-38 | 4 SYRINGE in 1 CARTON (0245-0809-38) / 1 INJECTION, SOLUTION in 1 SYRINGE (0245-0809-89) |
| ZEMBRACE SYMTOUCH | sumatriptan succinate | SOLUTION;SUBCUTANEOUS | 208223 | NDA | Tonix Medicines, Inc. | 70792-809 | 70792-809-38 | 4 BLISTER PACK in 1 CARTON (70792-809-38) / 1 SYRINGE in 1 BLISTER PACK / .5 mL in 1 SYRINGE |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;SUBCUTANEOUS | Strength | EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML) | ||||
| Approval Date: | Jan 28, 2016 | TE: | RLD: | Yes | |||||
| Patent: | 10,537,554 | Patent Expiration: | Jan 29, 2036 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF MIGRAINE | ||||||||
| Patent: | 11,364,224 | Patent Expiration: | Jan 29, 2036 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF MIGRAINE | ||||||||
| Patent: | 12,097,183 | Patent Expiration: | Jan 29, 2036 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Complete Access Available with Subscription
